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Discussion
Controlled trials of treatment in Bell's palsy are difficult to perform because of delay in starting therapy which is likely to prejudice the result. For this reason the patients were subdivided into early and late groups. Sixty-six started treatment on the first or second day of paralysis and 120 on the third or fourth days. The results of earlier treatment were indeed better, though both groups showed benefit. However, in very severe attacks the major damage may be done within the first few hours and treatment should be started at once.
It has previously been shown that the outcome in untreated Bell's palsy becomes worse with increasing age (Langworth and Taverner, 1963) so the patients were further subdivided into young and older groups. There were 104 patients in the young group and 82 in the older group. The expected difference was observed, but in the whole series the mean age of the patients who developed denervation was 44-6 years for the corticotrophin group and 43 9 years for the prednisolone group.
Assessment of the result of treatment is a difficult problem even if very elaborate methods are used. The presence or absence of denervation can be determined by the appearance of associated movements (Langworth and Taverner, 1963) , and this is the strictest criterion available. The results now reported are based almost entirely on this finding. We are well aware of the unreliability of subjective estimates of the difference in movement of the two sides of the face, but the statistically significant differences reported here are considerable and it is unlikely that observer error is responsible. The actual assessments of recovery in the severely denervated patients receiving corticotrophin mentioned above were 10%, 15%, 10%, 10%, 15%, and 15%, while all who took prednisolone were assessed at 50% recovery or above.
We had hoped to show that corticotrophin injections gave better results than oral prednisolone if only because a previous trial of cortisone for Bell's palsy gave a negative result (Tavemer, 1954) . In retrospect it is clear that the 1954 trial was intadequately planned to produce a reliable result. The treatment was started far too late to be effective, the dose of cortisone was too low, and the number of patients tested was too small.
At present we believe that oral prednisolone is the treatment of choice in Bell's palsy and should be given in full doses from the day of onset. The small risk of serious side effects is acceptable in view of the significant reduction in the incidence of severe denervation.
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Introduction
The treatment of persistent dyskinesia associated with prolonged phenothiazine therapy has been unsatisfactory. Brandrup (1961) reported success with tetrabenazine in four patients (but we could find no further report on the value of this drug) and Roxburgh (1970) used thiopropazate successfully in two patients. Thiopropazate hydrochloride (Dartalan) is chemically described as 10-(3[4-(2-acetyoxyethyl)piperazin-1-yl]propyl)-2-chlorophenothiazine dihydrochloride and is a phenothiazine structurally closely related to chlorpromazine. It has been reported to be of value in schizophrenia (Hamilton et al., 1960) . Reports on its effectiveness in controlling choreiform movements have been confined to Huntingdon's chorea (Mathews, 1958; Bruyn, 1962; Lyon, 1962) apart from, so far as we can trace, one case each of non-hereditary chorea (Lyon, 1962) , probable senile chorea with polycythaemia (Heathfield, 1968) , and Sydenham's chorea activated by oral contraceptives (Lewis and Harrison, 1969) . Kabat and McLeod (1959) reported improvement of involuntary movements in 24 cases of cerebellar ataxia and intention tremor.
Persistent dyskinesia affecting the face, mouth, tongue, and jaw (oral dyskinesia) is well known as an insidious and late development of protracted phenothiazine intake. The syndrome has been reviewed by Crane (1968) and Kline (1968) and its relation to other phenothiazine-induced dysfunctions discussed by Faurbye (1970) . Some of the patients also showed dyskinesia affecting the neck, limbs, and trunk, manifesting usually as generalized restlessness or minor choreiform movements at the extremities (Faurbye et al., 1964; Hunter et al., 1964; Pryce and Edwards, 1966) . More violent generalized choreiform movements may also occur (Druckman et al., 1962; Roxburgh, 1970; Singer and Wong, 1970) .
While there is general agreement that the above syndrome exists, there is divergence of opinion on its frequency, aetiology, and clinical characteristics. The relation between dyskinesia and phenothiazines has not been finally established but the evidence strongly suggests it exists. Apart from the known effect of phenothiazines on the extrapyramidal system, the dosage of phenothiazine seems to have a direct bearing on the development of dyskinesia (Pryce and Edwards, 1966) . Kline (1968) All the patients in the trial were inpatients (22 Chinese, 1 Eurasian) of both sexes in Castle Peak Hospital which has 1,700 patients and is the only psychiatric hospital for the whole of Hong Kong's four mlllion population. All patients in the hospital were screened for cases of persistent dyskinesia and 23 were found that fulfilled the following criteria: (1) they had dyskinesia (see below for definition); (2) the dyskinesia had persisted unchanged for at least one month after phenothiazine withdrawal; (3) onset of dyskinesia was at least one year after the start of phenothiazine treatment; (4) the original diagnosis 23 was a functional psychosis; and (5) there was no organic disorder present known to cause involuntary movements, such as Huntington's chorea, senile and other choreas and athetoses, presenile and senile dementia, or a family history of involuntary movements or dementia. While every effort was made to obtain a homogenous group, and particularly to exclude cases with an organic "flavour," it was impracticable to exclude those who had had electric convulsion therapy (all patients) and leucotomy (two patients).
DEFINITION OF DYSKINESIA
By dyskinesia was meant involuntary, stereotyped, and rhythmic movements which included choreiform, choreo-athetotic, and athetotic movements, as follows. (1), Oral dyskinesia, in which one or more of the following regions were involved: tongue (as exemplified by forwards and backwards, side-to-side, torsion, and rotatory movements), lips (pursing, sucking, twisting, and opening and closing movements), face (grimacing movements), jaw (chewing and munching movements), and throat (dysarthria and swallowing difficulties). (2) Bodily dyskinesia, in which one or more of the following regions were involved: neck (spasmodic, writhing, nodding, torticollic, or retrocollic movements), limbs (choreic, athetotic, and choreoathetotic movements), trunk (spasmodic, writhing, and rotatory movements and respiratory irregularities).
Care was taken to exclude functional habit spasms and the mannerisms of psychotics. One-sixth of the patients selected also had mild to moderate Parkinsonism (rigidity).
ASSESSMENT
Patients were evaluated the day before the trial and at three and six weeks. Complete psychiatric and physical examinations were carried out on each occasion and reporting forms completed. Patients were also seen at weekly intervals at least and separate entries were made in their case notes. Dyskinesia was rated according to rating scales constructed to quantify the observations for statistical analysis. Three rating scales were devized to cover possibly different though overlapping aspects of the dyskinesia.
Global.-The rating was by general overall impression of the intensity and extept of dyskinesia. Scoring was from 0 for absent to 4 for severe dyskinesia (violent, ceaseless movements involving at least the whole of one region-face, neck, trunk, limbs).
Multidimensional. Interobserver test reliability was estimated by a comparison of the ratings in 17 patients using all three scales and carried out by one of us (C.M.N.) and an independent colleague. The coefficient of correlation of the ratings was 096 for the global, 0-87 for the multidimensional, and 0-82 for the facial scales.
Changes in the patients' psychiatric condition were also evaluated by comparing the condition the day before the trial with that at three and at six weeks. Changes were rated on a seven-point scale ranging from a score of -3. for much worse through 0 for no change to 3 for marked improvement. All the ratings were carried out by C.M.N. with the patients sitting unoccupied.
STATISTICAL METHODS
Significance of differences related to effect of clinical variables on response was determined by the x2 test (incorporating correction for continuity), and those related to a comparison of clinical characteristics which involve proportions in groups A and B by the standard test based on normal distribution. Significance of differences in placebo groups A and B was determined by the standard t test, fractional improvement scores being used to eliminate possible differences between their pretrial scores. All other probabilities reported were based on Student's t test for paired observations. It was realized at the outset that the tests based on Student's t and normal distribution were valid only for normally and independently distributed normal variates. This fact was borne in mind in ihe construction of the three rating scales and the scoring system. The t test was also preferred to the nonparametric Wilcoxon's signed ranks test, since the proportion of tied ranks in the data was relatively high.
Results
All 23 patients selected completed the six weeks' trial. On breaking the code it was found that 12 belonged to group A and 11 to group B. The dosage did not have to be varied because of side effects or for other reasons.
The mean age of the patients was 52-1 years (S.D. 13-1); nine were males and 14 females; and 21 were schizophrenic and two affective. The mean length of psychotic illness (including periods of remission) was 11x3 years (S.D. 7T0), of dyskinesia 22-1 months (S.D. 33 2), of phenothiazine treatment 8-2 years (S.D. 4 2), and of dyskinesia after phenothiazine withdrawal 6 2 months (S.D. 7-1). Eleven had only facial involvement and the remainder had also bodily involvement. Groups A and B were found not to differ significantly except for distribution of dyskinesia.
It will be seen ( Table I ) that thiopropazate more effectively relieved dyskinesia than placebo. The difference is statistically significant in all three rating scales. Also on thiopropazate 18 were improved, three unchanged, and two worse. dyskinesia did not influence the response to thiopropazate (or to placebo) according to all three rating scales.* Possible side effects were noted in eight patients receiving thiopropazate-six had Parkinsonism, mainly in the form of rigidity, and four drowsiness. Four patients had had Parkinsonian rigidity before the trial so that some of this seen during the trial was probably not attributable to the drug. None had side effects while on placebo. The Parkinsonism was severe in only one patient, in whom it was relieved by benzhexol.
Thiopropazate and placebo scores with the psychiatric rating scale were compared. Thiopropazate was significantly better than placebo in improving psychotic behaviour (Table II) . It is noteworthy that the supposedly distinctive features of persistent or tardive dyskinesia-total duration of dyskinesia, duration of dyskinesia after phenothiazine withdrawal, lateness of onset, and oral involvement-had no correlation with response to thiopropazate. This suggests that these features do not characterize and demarcate the syndrome from dyskinesia of short duration, early onset, and affecting other bodily regions induced by phenothiazines. It is also interesting that the severity of dyskinesia, which implies the extent of the damage induced by phenothiazines, had no bearing on response.
It is reasonable to assume that thiopropazate was responsible for some of the Parkinsonism seen during the trial since, though one-sixth of the patients had Parkinsonism before, one-quarter had it during the trial. Also the drug is known to cause Parkinsonism. The therapeutic benefit was to an extent vitiated by this side effect, which can be ameliorated by a reduction in dosage. Experience from the trial showed that 15 mg three times a day was too high an average dose.
The mode of action of thiopropazate in improving involuntary movements is unknown. It seems paradoxical that thiopropazate, a phenothiazine, should be effective in a syndrome probably induced by other phenothiazines. However, thiopropazate has been reported to be effective in the superficially similar syndrome of Huntington's chorea and was on this basis first used to treat oral dyskinesia (Roxburgh, 1970) . Another example of an apparently paradoxical effect is the exacerbation of phenothiazine-induced dyskinesia after phenothiazine withdrawal *Statistical details for these and other comparisons may be obtained from the authors. (Kennedy, 1969) . Also reminiscent of this sort of effect is the Parkinsonism associated with the phenothiazines used in psychiatry compared with the opposite effect of the anticholinergic phenothiazines-for example, diethazine.
In conclusion, thiopropazate seems to be an effective drug in the short term for persistent dyskinesia. This finding, if confirmed, is clinically useful in view of the increasing frequency with which the condition is being reported and its lack of response to other treatment. Whether thiopropazate can be recommended as the phenothiazine of choice in those predisposed to dyskinesia, such as the elderly and brain-damaged, cannot be decided at this stage, since its antipsychotic value relative to that of other phenothiazines has to be considered.
